Kara Miller, PA-C
Kara Miller, PA-C
Specialty: Medical Oncology
Program: Gastrointestinal Oncology
Language(s): English
-
Overview
Cancer Focus:
Anal Cancer, Colon Cancer, Colorectal Cancer, Rectal CancerKara Miller is a certified Physician Assistant specializing in medical oncology in the Gastrointestinal Tumor Department. She has been practicing in medical oncology since 2013 and has been focusing in lower GI malignancies at Moffitt since 2018. Prior to becoming a Physician Assistant, she worked in the Drug Discovery Department at Moffitt where she investigated small molecules in in vitro and in vivo tumor models. Mrs. Miller completed her physician assistant training at Nova Southeastern University in Jacksonville, FL and earned her Bachelor degree at the University of Florida. She is board certified by the National Commission on Certification of Physician Assistants and licensed by the State of Florida Board of Medicine.
-
Publications
- Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Brit J Cancer. 2014 Aug.111(5):894-902. Pubmedid: 24983364. Pmcid: PMC4150266.
- Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012 Oct.72(19):5025-5034. Pubmedid: 22846914. Pmcid: PMC3463757.
- Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun.3(6):699-709. Pubmedid: 23275831. Pmcid: PMC3531244.
- Balasis ME, Forinash KD, Chen YA, Fulp WJ, Coppola D, Hamilton AD, Cheng JQ, Sebti SM. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res. 2011 May.17(9):2852-2862. Pubmedid: 21536547. Pmcid: PMC3156694.
-
Patient Comments
129 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments